04 June 2020 | News
TENELIA®, originating in Japan, is a dipeptidyl peptidase-4 (DPP-4) inhibitor discovered by MTPC
Image credit- shutterstock.com
Japan based Mitsubishi Tanabe Pharma Corporation (MTPC) has announced that MTPC’s subsidiary in Thailand obtained the regulatory approval of TENELIA® (generic name; teneligliptin hydrobromide hydrate; Japan name: TENELIA® 20mg tablets) for a treatment agent for type 2 diabetes mellitus from Food and Drug Administration Thailand, following the completion of the approval application procedure.
In Thailand, Mitsubishi Tanabe Pharma (Thailand) Co., Ltd., the locally based subsidiary of MTPC, will market as the Marketing Authorization Holder (MAH) teneligliptin under the name TENELIA®.
TENELIA®, originating in Japan, is a dipeptidyl peptidase-4 (DPP-4) inhibitor discovered by MTPC. TENELIA® has made it highly effective in lowering each of the postprandial blood glucose levels, as well as fasting blood glucose levels, with once- a-day administration. TENELIA® needs no dose adjustments according to the levels of renal or hepatic dysfunction, so that TENELIA® can be used to treat a wide range of patients with diabetes.
MTPC filed teneligliptin to Asian countries including China and is working to get early approval to bring this product to patients as soon as possible.
By providing a new option for the treatment of diabetes to a growing number of patients in the world, MTPC shows its continued resolve to improve their quality of life (QOL).